{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:36:31Z","timestamp":1769603791022,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s11739-014-1181-5","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T08:18:36Z","timestamp":1421223516000},"page":"21-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?"],"prefix":"10.1007","volume":"10","author":[{"given":"Giuseppe","family":"Di Pasquale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Zagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","volume":"14","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385\u20131413","journal-title":"Europace"},{"key":"1181_CR2","first-page":"215","volume":"14","author":"A Raviele","year":"2013","unstructured":"Raviele A, Disertori M, Alboni P et al (2013) Linee guida AIAC per la gestione e il trattamento della fibrillazione atriale. Aggiornamento 2013. G Ital Cardiol 14:215\u2013240","journal-title":"G Ital Cardiol"},{"key":"1181_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 146:857\u2013867","journal-title":"Ann Intern Med"},{"issue":"2","key":"1181_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"YH Lip","year":"2010","unstructured":"Lip YH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272","journal-title":"Chest"},{"key":"1181_CR5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","volume":"306","author":"WB Kannel","year":"1982","unstructured":"Kannel WB, Abbott RD, Savage DD, McNamara PM (1982) Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306:1018\u20131022","journal-title":"N Engl J Med"},{"key":"1181_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","volume":"16","author":"P Kirchhof","year":"2014","unstructured":"Kirchhof P, Ammentorp B, Darius H, De Caterina R et al (2014) Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF). Europace 16:6\u201314","journal-title":"Europace"},{"key":"1181_CR7","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm J, Olsson SB, Andresen D, Davies DW et al (2005) Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26:2422\u20132434","journal-title":"Eur Heart J"},{"key":"1181_CR8","author":"M Molteni","year":"2014","unstructured":"Molteni M, Friz HP, Primitz L et al (2014) The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey. Europace. doi: 10.1093\/europace\/euu178","journal-title":"Europace"},{"key":"1181_CR9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","volume":"16","author":"GY Lip","year":"2014","unstructured":"Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al (2014) A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of Euro Observational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16:308\u2013319","journal-title":"Europace"},{"key":"1181_CR10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.ijcard.2012.07.019","volume":"167","author":"G Pasquale Di","year":"2013","unstructured":"Di Pasquale G, Mathieu G, Maggioni AP et al (2013) On behalf of ATA-AF Investigators. Current presentation and management of 7,148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: The ATA AF study. Int J Cardiol 167:2895\u20132903","journal-title":"Int J Cardiol"},{"key":"1181_CR11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejim.2013.04.008","volume":"24","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Di Pasquale G, Vescovo G et al (2013) Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study. Eur J Intern Med 24:324\u2013332","journal-title":"Eur J Intern Med"},{"key":"1181_CR12","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009) RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u201351","DOI":"10.1056\/NEJMoa0905561"},{"key":"1181_CR13","doi-asserted-by":"crossref","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. ROCKET-AF Investigators (2011) Rivaroxaban vs. warfarin in non-valvular atrial fibrillation. N Engl J Med 365:883\u201391","DOI":"10.1056\/NEJMoa1009638"},{"key":"1181_CR14","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Eikelboom J, Joyner C et al. on behalf of AVERROES Steering Committee and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 2011 Mar 3;364:806\u2013817","DOI":"10.1056\/NEJMoa1007432"},{"key":"1181_CR15","doi-asserted-by":"crossref","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","DOI":"10.1056\/NEJMoa1107039"},{"key":"1181_CR16","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","DOI":"10.1056\/NEJMoa1310907"},{"key":"1181_CR17","unstructured":"Ezekowitz MD, Parise H, Nagarakanti R et al. (2014) Abstract \u201cInnovation and Intervention\u201d of the American College of Cardiology"},{"key":"1181_CR18","doi-asserted-by":"crossref","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD et al. (2014) Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (Epub ahead of print)","DOI":"10.1093\/eurheartj\/ehu305"},{"key":"1181_CR19","doi-asserted-by":"crossref","unstructured":"Avezum A, Lopes RD, Schulte PJ et al. Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study. Abstract 4384, ESC Congress 2013","DOI":"10.1093\/eurheartj\/eht310.4384"},{"key":"1181_CR20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/14779072.2014.960851","volume":"12","author":"JM Blustin","year":"2014","unstructured":"Blustin JM, McBane RD, Ketha SS et al (2014) Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation. Expert Rev Cardiovasc Ther 12:1129\u20131132","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1181_CR21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/heartjnl-2012-301799","volume":"98","author":"R Mahajan","year":"2012","unstructured":"Mahajan R, Brooks AG, Sullivan T et al (2012) Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure. Heart 98:1120\u20131126","journal-title":"Heart"},{"key":"1181_CR22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/CIRCIMAGING.113.000253","volume":"6","author":"SA Luis","year":"2013","unstructured":"Luis SA, Poon K, Luis C, Shukla A, Bett N, Hamilton-Craig C (2013) Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran. Circ Cardiovasc Imaging 6:491\u2013492","journal-title":"Circ Cardiovasc Imaging"},{"key":"1181_CR23","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Connoly SJ, Brueckmann M et al. for the RE-ALIGN Investigators (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 369:1206\u20131214","DOI":"10.1056\/NEJMoa1300615"},{"key":"1181_CR24","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","volume":"33","author":"The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC)","year":"2012","unstructured":"The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), The European Association for Cardio-Thoracic Surgery (EACTS) (2012) Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33:2451\u20132496","journal-title":"Eur Heart J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-014-1181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-014-1181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-014-1181-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T18:11:24Z","timestamp":1566238284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-014-1181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s11739-014-1181-5","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,15]]}}}